{"id":"taclonex-topical-suspension","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation or burning"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Skin atrophy (with prolonged use)"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcipotriene acts as a vitamin D receptor agonist that promotes differentiation and reduces proliferation of keratinocytes, while betamethasone dipropionate provides potent anti-inflammatory effects through glucocorticoid receptor activation. Together, these agents work synergistically to reduce the erythema, scaling, and plaque formation characteristic of psoriasis.","oneSentence":"Taclonex combines calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:10:48.854Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT01120223","phase":"PHASE2","title":"Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-05","conditions":"Scalp Psoriasis","enrollment":78},{"nctId":"NCT01083758","phase":"PHASE2","title":"Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-04","conditions":"Scalp Psoriasis","enrollment":31},{"nctId":"NCT01229098","phase":"PHASE2","title":"Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-10","conditions":"Psoriasis Vulgaris","enrollment":102},{"nctId":"NCT03880357","phase":"PHASE1","title":"To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2018-10-22","conditions":"Scalp Psoriasis","enrollment":485},{"nctId":"NCT03331523","phase":"PHASE3","title":"To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2017-10-20","conditions":"Scalp Psoriasis","enrollment":643},{"nctId":"NCT01707043","phase":"PHASE4","title":"Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2012-10","conditions":"Plaque Psoriasis","enrollment":20},{"nctId":"NCT03122353","phase":"PHASE1","title":"BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Tolmar Inc.","startDate":"2017-04-11","conditions":"Scalp Psoriasis","enrollment":699},{"nctId":"NCT01982552","phase":"","title":"An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-07","conditions":"Psoriasis Vulgaris","enrollment":147},{"nctId":"NCT01761019","phase":"PHASE4","title":"A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-01","conditions":"Psoriasis","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Taclonex Topical Suspension","genericName":"Taclonex Topical Suspension","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Taclonex combines calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}